J'achète l'étude complète
Synthèse
The global insulin pump market, valued at US$5.67 billion in 2022, is expected to grow at a CAGR of 8.8%, reaching US$9.4 billion by 2028. Driven by a sharp rise in the prevalence of diabetes worldwide, particularly in regions such as Africa, Asia-Pacific and the Middle East, this market is experiencing significant growth.In 2021 alone, the global diabetes population grew by 74 million to 537 million, with forecasts of 643 million by 2030 and 783 million by 2045. In Asia-Pacific, the Middle East, North Africa and Africa, the diabetic population could more than double by 2045 compared with 2021.
The French market, with an average annual growth rate of 6.58%, and spending such as the 9,576 million euros allocated to diabetes care by the French health insurance system in 2021, reflect the robust dynamics of this sector. Innovations and the introduction of advanced insulin pump models, such as Medtronic's Minimed 780G, Omnipod DASH and Tandem's t:slim X2, meet the needs of an increasingly aware diabetic population. Despite a diverse market landscape, major entities like Medtronic, Roche and others dominate the scene, focusing on connected technologies and more patient-friendly solutions to improve diabetes management.
Insulin pump market trends and dynamics in France
The French insulin pump market is demonstrating considerable dynamism and growth potential, being one of the leading consumers of diabetes treatments in Europe. While the value of the global market is set to increase, with estimates reaching between US$5 and US$10 billion by 2028, France reflects this momentum with a CAGR of around 6-7% between 2023 and 2028.
France faces major challenges in diabetes care, with around 3 to 4 million people being treated, and an alarming estimate that almost a million French citizens are undiagnosed. Despite a slight drop in 2020, the number of people receiving care has again risen substantially, reaching over 4 million in 2021. Notably, type 2 diabetes dominates the landscape, accounting for 92% of cases, with type 1 and other rarer forms making up the remainder. Those most affected are the over-65s, who account for over 60% of the diabetic population, with men slightly outnumbering women in terms of prevalence. Territorial disparities within France reveal that regions such as the French overseas departments and areas like Hauts-de-France and Grand-Est have higher prevalence rates than the national average. Diabetes also coincides with co-morbidities such as cardiovascular disease, psychotropic medication use, cancer and chronic respiratory conditions.
A significant trend in insulin pump use in France indicates that while almost 860,000 people are on insulin therapy, only 2-5% of diabetics use insulin pump technology, compared with 25% in the USA. However, this landscape is changing with the steady increase in insulin pump adoption among French diabetics. The number of users has increased almost fourfold to 82,000. Market expansion is also being driven by health insurance reimbursements, which play a central role in the accessibility of these devices. Such growth indicates an increasing trend in pump use, further amplified by the inclusion of new models such as the Minimed™ 780G, Omnipod DASH™.
Key manufacturers dominating the insulin pump landscape
The constantly evolving insulin pump market is driven by leading manufacturers who have established formidable positions within the healthcare industry, due to their in-depth expertise, innovative technologies and extensive range of products meeting the diverse needs of diabetic patients. Below are the main players who have made significant advances in the insulin pump market:
- Medtronic Medtronic is a pioneer in medical technology, particularly in the field of insulin pumps. The company boasts a solid product range that is well received the world over. Among its flagship products, the MiniMed 640G represents Medtronic's commitment to advanced diabetes management solutions. Although the company has decided to cease production of internally implanted insulin pumps, it continues to influence the market with its external devices and is recognized for its contribution to the evolution of modern diabetes care.
- Roche is a pillar of the insulin pump market under the banner of its Accu-Chek brand, known for its reliability and precision. Despite fierce competition from specialists such as Medtronic and Abbott, Roche continues to innovate, striving to breathe new life into its offerings in the diabetes sector. The company is seeking to establish itself in the market by launching products such as the Eversense continuous glucose monitor, building on the success of its flagship products, the Accu-Chek Insight and Accu-Chek Spirit Combo.
- Insulet is renowned for its revolutionary Omnipod device, which challenges traditional pump designs with its tubeless patch, enabling simplified management and three days of continuous insulin delivery. This approach has brought a new level of comfort and convenience to insulin pump users, and positioned Insulet as a key player intent on reshaping diabetes treatment.
- Ypsomed made its mark on the market with the myLife Ypsopump, an intuitive, connected pump with a user-friendly interface. Its clear commitment to marrying technology with patient-friendliness makes Ypsomed a reference name for those seeking modern treatment tools.
- Cellnovo Although smaller than the other players, Cellnovo continues to attract attention with its unique range of insulin pumps, including the Gen 3 and Gen 2 models. Known for pushing the boundaries of design and functionality, Cellnovo appeals to a niche segment that values innovation and user-centric features in diabetes treatment.
These key players have helped shape the landscape of the insulin pump market, each bringing their own distinct perspectives and specialist knowledge
à la compréhension de ce marché
Détail du contenu
Informations
- Nombre de pages : 30 pages
- Format : Version digitale et PDF
- Dernière mise à jour : 10/10/2023
Sommaire et extraits
1 Market overview
1.1 Insulin pump market overview and definition
The insulin pump is a treatment method for diabetics. It is an an interesting alternative to multi-injection therapy insulin injections, helping to maintain better glycemic control. Mimicking the functioning of a normal pancreas, it is an artificial device that delivers insulin at a variable rate to an insulin-dependent diabetic requiring insulin on a permanent basis.
Theinsulin pump can be implanted (rarely prescribed by physicians) or external (subcutaneous injection) . Operation is straightforward, with in-hospital training and regular follow-up with the diabetologist and pump vendor.
The global insulin market is growing, dominated by a handful of very powerful laboratories offering insulin pens and oral medications. Insulin pump sales constitute one segment of the insulin treatment market.
The insulin pump market segment is also growing, and is set to remain so for years to come, driven by the various innovations proposed by traditional and emerging players. This global market is estimated atUS$5.67 billion in 2022, andshould reach US$9.4 billion in 2028 (at aCAGR of 8.8%). [GrandViewResearch]
Indeed, in 2021, there will now be 537 million diabetics in the world, 3.5 times more than in 2000. Between 2019 and 2021, for example, the number of diabetics rose by 74 million. To date, Asia-Pacific has the highest number of people with diabetes (206 million), but the increase is expected to beparticularly strong in Africa (+134% in 2045 compared with 2021) [DiabetesAtlas]
France is one of Europe's biggest consumers of diabetes treatments, with healthcare expenditure linked to this disease amounting to over 22 billion euros in 2021[DiabetesAtlas]. As a result, the insulin pump market is highly dynamic, and is expected to grow at a CAGR of 6.58% over the period 2023-2028. [Mordor Intelligence]
The market for diabetes treatment is very closely linked to the regulations and healthcare system in place. For example, the French social security system allows insulin pump treatment to be reimbursed, and regularly updates the new pumps that are eligible for reimbursement.
1.2 The global market
The global insulin pump market is estimated at US$*.** billion in ****, and is expected to continue growing over the next few years at a CAGR of *.*%, reaching US$*.* billion in ****.
Insulin pump market size World, **** - ****, in billions of USD Source: GandViewResearch (***) : projection
Global market growth drivers include the rising number ...
1.3 Growth in the French market
The following graph shows the evolution of diabetes-related healthcare expenditure in France. This figure includes all diabetes-related expenses in France. It includes, for example, all the costs of insulin therapy, visits to healthcare professionals and equipment, as well as all the resources devoted to prevention, nutrition and so on. It also ...
2 Demand analysis
2.1 The profile of diabetes patients
The number of diabetics under care is trending upwards in France, rising from *.* million in **** to * million in ****, an increase of **% in just * years. However, by ****, the number of people in care would have fallen by ***,***, before rising again by ***,*** in ****, to around *.* million.
People treated for diabetes in **** (***) France, **** - ...
2.2 Obesity and overweight as risk factors
Obesity and diabetes are two closely related diseases. In fact, according to the Pasteur Institute in Lille, obesity is the leading risk factor for diabetes, and **% of obese people also suffer from diabetes. The increase in obesity and overweight is the main reason for the sharp rise in the number of ...
2.3 Insulin pump users among diabetics
Of the *,***,*** diabetic patients who were treated in ****, (***).
According to Has-Santé, the population of French patients using external insulin pumps stood at **,*** in ****. This would mean that only *% of diabetics would be using this device. According to lvlmedical, however, *% of diabetics will be using an insulin pump. by way of comparison, ...
3 Market structure
3.1 The central role of health insurance and reimbursements
The French Assurance Maladie plays a central role in the insulin pump market, as it does for many drugs, treatments and medical equipment. As diabetes is classified as a long-term condition (***), costs are ***% covered by the French health insurance system, whether for diabetes-related care or for complications: ocular, vascular, renal or ...
3.2 The main players in the diabetes treatments market
The global market for anti-diabetic treatments is not very fragmented, and is dominated by a handful of large international groups. Evaluate Pharma provides annual reports on the global pharmaceutical market, but only the **** report focuses on the anti-diabetic market.
In ****, the top ** groups accounted for over **% of total market value, including ...
3.3 Leading insulin pump manufacturers
The French insulin pump market is highly fragmented and dominated by a handful of industry giants .
Medtronic
Sales of the Medtronic group's Diabetes division have grown steadily in recent years, from $*.** billion in **** to $*.** billion in ****. A world leader in medical technologies, the group has a very strong presence in the ...
4 Offer analysis
4.1 Insulin pump typology
Insulin pumps are medical devices used in the treatment of diabetes (***). Compared with multi-injection therapy, the insulin pump enables patients to maintain a freer, more flexible lifestyle, with greater flexibility in mealtimes, as well as better monitoring of blood glucose levels, and therefore a lower risk of complications.
The insulin pump ...
4.2 Product innovation on the market
Digital technology in diabetes treatment
Manufacturers in the insulin therapy market are increasingly investing in the connected objects segment to meet consumer expectations. For example, Abbott and Sanofi, as well as Medtronic and Novo Nordisk, have signed alliances in **** to advance in the connected pen segment.
In particular, Abbott has launched ...
5 Regulations
5.1 Supervision of insulin pump therapy
Prescriptions[***]
Insulin pumps are reimbursed by the French national health insurance scheme (***) for type * and type * diabetes which cannot be controlledby insulin therapy using multiple subcutaneous injections of insulin.
The initial prescription for an external insulin pump (***) must be made in an initiating center. This prescription is valid for a maximum ...
6 Positioning the players
6. Segmentation
- Medtronic
- Cellnovo
- Roche Diabetes Care (Roche Groupe)
- Insulet
- Ypsomed Group
- ISIS diabète (Isis Médical)
- Physidia
- Nova Medical Center
- Medtrum
- Apex Wellell
- Open APS
- Eli Lilly
- TreeFrog Therapeutics
- Boydsense
Liste des graphiques
- Taille de marché des pompes à insuline
- Répartition du nombre de diabétiques selon les régions du monde
- Répartition des diabétiques selon les régions du monde
- Evolution du nombre de diabétiques dans le monde
- Pays avec le plus grand nombre de diabétiques
Toutes nos études sont disponible en ligne et en PDF
Nous vous proposons de consulter un exemple de notre travail d'étude sur un autre marché !
Dernières actualités
Biotech : à Bordeaux, TreeFrog reçoit 700 millions pour produire des cellules souches par milliards - 23/04/2024
- La biotech TreeFrog Therapeutics a signé un accord commercial et industriel avec le leader mondial des thérapies cellulaires Vertex Pharmaceuticals
- TreeFrog vend au laboratoire américain une licence mondiale de sa technologie de production de cellules souches dans le diabète de type 1 pour un montant qui pourrait lui permettre de recevoir jusqu'à 730 millions d'euros.
- La société girondine va recevoir un paiement initial de 23,5 millions d'euros, puis 202 millions d'euros supplémentaires en différentes étapes
- Ces droits de licence qui pourraient atteindre 765,5 millions d'euros
- TreeFrog a déjà levé près de 70 millions d'euros en capital
Boydsense réinvente la mesure de la glycémie dans l'haleine - 23/04/2024
- Filiale de la société d'analyse sensorielle Alpha MOS
- L'entreprise toulousaine vient de lever 7 millions d'euros pour développer son dispositif d'analyse du taux de glycémie des diabétiques dans l'haleine, et non dans le sang .
- Aujourd'hui, les diabétiques mesurent leur taux de glycémie en se piquant le doigt pour analyser une goutte de sang avec un boîtier.
- Le futur dispositif leur permettra de le faire sans se piquer et plusieurs fois par jour.
- La société toulousaine a conçu un algorithme d'analyse et réalisé un prototype fonctionnel
- on dénombre 500 millions de diabétiques dans le monde
Lilly France mise sur l'Alsace pour ses médicaments antidiabète - 15/01/2024
- Le laboratoire Eli Lilly a déjà investi 389 millions d'euros en cinq ans dans son complexe de Fegersheim.
- Un investissement supplémentaire de 160 millions d'euros est prévu par Lilly France.
- Le site emploie actuellement 1200 personnes
- 107 millions d'euros seront alloués à la construction d'une ligne de remplissage aseptique pour produire un nouveau médicament contre le diabète de type 2
- 35 millions d'euros seront investis pour ajouter une nouvelle ligne de production de stylos injecteurs à partir de 2025.
- 18 millions d'euros seront utilisés pour construire un bâtiment de stockage et produire de l'eau purifiée.
Columna Capital installe Julien Dolivet à la tête de Physidia - 28/11/2023
- Fabricant d'appareils d'hémodialyse
- Année de création de Physidia : 2010 à Angers
- Nouveau propriétaire : Columna Capital (Société d'investissement basée à Londres
- Chiffre d'affaires de Physidia en 2018 : 7,2 millions d'euros, a en 2022 : 22 millions d'euros
- Nombre d'employés : 60
- Nombre d'appareils S3 vendus : Plus de 1 000 dans 16 pays européens
- Objectif de croissance du chiffre d'affaires : Tripler en 3 à 5 ans
- Part du marché de l'hémodialyse à domicile : 1 à 2 % (sans compter les dialyses péritonéales)
- Pourcentage de séances d'hémodialyse effectuées en centre : 90 %
Lilly investit 2,3 milliards d’euros pour une usine en Allemagne - 25/11/2023
- Lilly a annoncé un investissement de 2,5 milliards de dollars (2,3 milliards d'euros) dans une nouvelle usine en Allemagne.
- La mise en service de la nouvelle usine est prévue pour 2027.
- L'usine emploiera jusqu'à 1 000 personnes.
- Il s'agit de la sixième installation européenne du laboratoire américain.
- Ce laboratoire a investi 160 millions d'euros dans son site français, à Fegersheim (Bas-Rhin).
- Au cours des trois dernières années, Lilly a investi plus de 11 milliards de dollars dans ses opérations industrielles dans le monde.
- Le laboratoire concurrent Novo Nordisk a récemment annoncé qu'il investirait également plusieurs milliards d'euros au Danemark pour soutenir sa production.
Lilly va produire le médicament star du diabète et de l'obésité en Alsace - 23/10/2023
- L'usine de Fegersheim en Alsace est la troisième plus grosse des sept usines mondiales de Lilly avec environ 1.250 employés (en baisse depuis 1.400 en 2019).
- Le site de Lilly à Indianapolis compte 2.000 employés.
- 96% de la production de l'usine française est exportée.
- L'usine française dessert 120 pays en insuline.
- Lilly a consacré 91 millions d'euros à l'antidiabétique Trulicity en 2022.
- Lilly investit 160 millions d'euros dans le Mounjaro.
- Les deux principaux acteurs du marché émergent de l'obésité sont Lilly et Novo.
- On estime que d'ici 2030, ce marché générera entre 77 et 100 milliards de dollars de ventes par an.
Entreprises citées dans cette étude
Cette étude contient un panorama complet des entreprises du marché avec les derniers chiffres et actualités de chaque entreprise :
Choisir cette étude c'est :
Accéder à plus de 35 heures de travail
Nos études sont le résultat de plus de 35 heures de recherches et d'analyses. Utiliser nos études vous permet de consacrer plus de temps et de valeur ajoutée à vos projets.
Profiter de 6 années d'expérience et de plus de 1500 études sectorielles déjà produites
Notre expertise nous permet de produire des études complètes dans tous les secteurs, y compris des marchés de niche ou naissants.
Notre savoir-faire et notre méthodologie nous permet de produire des études avec un rapport qualité-prix unique
Accéder à plusieurs milliers d'articles et données payantes
Businesscoot a accès à l'ensemble de la presse économique payante ainsi qu'à des bases de données exclusives pour réaliser ses études de marché (+ 30 000 articles et sources privées).
Afin d'enrichir nos études, nos analystes utilisent également des indicateurs web (semrush, trends…) pour identifier les tendances sur un marché et les stratégies des entreprises. (Consulter nos sources payantes)
Un accompagnement garanti après votre achat
Une équipe dédiée au service après-vente, pour vous garantir un niveau de satisfaction élevé. (+33) 9 70 46 55 00
Un format digital pensé pour nos utilisateurs
Vous accédez à un PDF mais aussi à une version digitale pensée pour nos clients. Cette version vous permet d’accéder aux sources, aux données au format Excel et aux graphiques. Le contenu de l'étude peut ainsi être facilement récupéré et adapté pour vos supports.
Nos offres :
the Insulin Pump Market | France
- Quels sont les chiffres sur la taille et la croissance du marché ?
- Quels leviers tirent la croissance du marché et leur évolution ?
- Quel est le positionnement des entreprises sur la chaine de valeur ?
- Comment se différencient les entreprises du marché ?
- Données issues de plusieurs dizaines de bases de données
Pack 5 études (-15%) France
- 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
- Conservez -15% sur les études supplémentaires achetées
- Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)
Consultez les conditions du pack et de remboursement des crédits non consommés.
- 23/04/2024 - Ajout des informations de l'entreprise Boydsense
- 23/04/2024 - Ajout des informations de l'entreprise TreeFrog Therapeutics
- 23/10/2023 - Ajout des informations de l'entreprise Eli Lilly
- 05/07/2023 - Ajout des informations de l'entreprise Open APS
- 05/07/2023 - Ajout des informations de l'entreprise Apex medical
- 05/07/2023 - Ajout des informations de l'entreprise Medtrum
- 05/07/2023 - Ajout des informations de l'entreprise Nova medical center
- 05/07/2023 - Ajout des informations de l'entreprise Roche
- 05/07/2023 - Ajout des informations de l'entreprise roches blanches
- 18/06/2023 - Ajout des informations de l'entreprise Physidia
- 17/06/2023 - Ajout des informations de l'entreprise ISIS diabète
Nos références clients
Ils ont consulté nos études
Découvrir les avis (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & Cas clients
Toutes les interviews et cas clients (45)
